ClinicalTrials.gg
CompletedNCT06605599CANTOUpdated Oct 14, 2026

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

A Phase 2 interventional study of ABBV-932 and Placebo for ABBV-932 in Bipolar I Disorder and Bipolar II Disorder, sponsored by AbbVie. Completed at 40 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2026.
Updated Oct 14, 20265 sites added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.

Enrollment
8th of 11
161 · median 234
Started
2024
the only one that year
Phase 2
6 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 8th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 2, and was the 9th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bipolar Disorder by AbbVie, or all of them as a file.
02

Study summary

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder.

ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide.

Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Bipolar I Disorder
  • Bipolar II Disorder

Browse trials for

Keywords

  • Bipolar I Disorder
  • Bipolar II Disorder
  • Bipolar Disorder
  • ABBV-932
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet , Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder without psychotic features based on the Mini International Neuropsychiatric Interview (MINI), with a current depressive episode of at least 4 weeks and not exceeding 12 months.
  • Have a minimum score of 20 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
  • Have a minimum score of 2 on Item 1 of the HAMD-17 at screening.

Exclusion criteria

Exclusion Criteria:

  • Positive urine drug screen (UDS) result at screening.
  • Treated with any drug within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug, is currently enrolled in another clinical study, or was previously enrolled in this study.
  • Current use of any antipsychotic, antidepressant, anticonvulsant, mood stabilizer, herb, or over-the-counter medication with psychoactive potential within 1 week or 5 half-lives of the medication (whichever is longer).
  • Prior exposure to ABBV-932 within 90 days prior to baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    ABBV-932 Dose A

    Participants will receive ABBV-932 Dose A.

    Drug: ABBV-932

  • Experimental
    ABBV-932 Dose B

    Participants will receive ABBV-932 Dose B.

    Drug: ABBV-932

  • Experimental
    ABBV-932 Dose C

    Participants will receive ABBV-932 Dose C.

    Drug: ABBV-932

  • Placebo comparator
    Placebo for ABBV-932

    Participants will receive placebo.

    Drug: Placebo for ABBV-932

Interventions

  • Oral Capsule

  • DrugPlacebo for ABBV-932

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

    Time frame: Up to Week 6

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression-Severity - Bipolar Disorder (CGI-S-BP)

    CGI-S-BP is a single-item clinician-reported measure of severity of bipolar disorder. Clinicians are asked to rate the severity of mania, depression, and overall bipolar illness. Response options range from 1 to 7: 1 = normal, not ill through 7 = very severely ill.

    Time frame: Up to Week 6

  2. Change From Baseline in Functioning Assessment Short Test (FAST) Total Score

    FAST is a clinician-reported outcome measure designed to assess the main functioning problems experienced by psychiatric participants, particularly bipolar participants. The FAST includes 24 items in 6 domains of functioning. Clinicians are asked to respond on a 4-point Likert scale ranging from 0 to 3 (0 = no difficulty and 3 = severe difficulty). Higher scores indicate greater difficulties in functioning.

    Time frame: Up to Week 6

  3. Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score

    HAM-A is a 14-item, clinician-reported measure used to quantify and categorize the participant's anxiety over the past week. Items are rated on a 5-point Likert rating scale of "absent" (0; if symptoms are absent, insignificant, or clearly due to causes other than anxiety) through "very severe" (4; if symptom is incapacitating). The HAM-A total score ranges from 0 to 56, with higher scores indicating greater anxiety severity.

    Time frame: Up to Week 6

07

Study locations

40 sites
  • Harmonex /ID# 267504
    Dothan, Alabama 36303, United States
  • Advanced Research Center /ID# 267716
    Anaheim, California 92805, United States
  • Axiom Research /ID# 267518
    Colton, California 92324, United States
  • Collaborative Neuroscience Research - Garden Grove /ID# 267654
    Garden Grove, California 92845, United States
  • Sun Valley Research Center /ID# 267708
    Imperial, California 92251, United States
  • Alliance for Research Alliance for Wellness /ID# 267492
    Long Beach, California 90807, United States
  • Excell Research /ID# 267541
    Oceanside, California 92056, United States
  • Viking Clinical Research Center - Temecula /ID# 267634
    Temecula, California 92591, United States
  • Accel Research Sites Network - St. Pete /ID# 267463
    Largo, Florida 33777, United States
  • GMI Florida - Central Miami Medical Institute /ID# 267566
    Miami, Florida 33125, United States
  • Allied Biomedical Res Inst Inc /ID# 267481
    Miami, Florida 33155, United States
  • K2 Medical Research - Orlando - South Orlando Avenue /ID# 267567
    Orlando, Florida 32751, United States
  • Segal Trials - West Broward Outpatient Research Site /ID# 267947
    Tamarac, Florida 33319-4985, United States
  • Benchmark Research /ID# 267626
    Shreveport, Louisiana 71101, United States
  • CenExel /ID# 267675
    Gaithersburg, Maryland 20877-1407, United States
  • Arch Clinical Trials /ID# 267507
    St Louis, Missouri 63125, United States
  • Duplicate_Oasis Clinical Research, LLC /ID# 267969
    Las Vegas, Nevada 89121, United States
  • Center For Emotional Fitness - Cherry Hill /ID# 267661
    Cherry Hill, New Jersey 08002, United States
  • Bio Behavioral Health /ID# 267493
    Toms River, New Jersey 08755, United States
  • Neurobehavioral Research /ID# 267564
    Cedarhurst, New York 11516, United States
  • New Hope Clinical Research - Inpatient unit /ID# 267465
    Charlotte, North Carolina 28211, United States
  • Quest Therapeutics of Avon Lake /ID# 267558
    Avon Lake, Ohio 44012, United States
  • OSU Psychiatry Department /ID# 267730
    Columbus, Ohio 43210, United States
  • Sooner Clinical Research /ID# 267639
    Oklahoma City, Oklahoma 73116, United States
  • Lehigh Center for Clinical Research /ID# 267451
    Allentown, Pennsylvania 18103, United States
  • Suburban Research Associates - Media /ID# 267621
    Media, Pennsylvania 19063, United States
  • Coastal Carolina Research Center, LLC /ID# 267550
    Charleston, South Carolina 29492, United States
  • FutureSearch Trials of Dallas /ID# 267715
    Dallas, Texas 75231, United States
  • Perceptive Pharma Research /ID# 267563
    Richmond, Texas 77407, United States
  • Grayline Research Center /ID# 267466
    Wichita Falls, Texas 76309, United States
  • Northwest Clinical Research Center /ID# 267505
    Bellevue, Washington 98007, United States
  • Core Clinical Research /ID# 268534
    Everett, Washington 98201, United States
  • Kaku Mental Clinic /ID# 268020
    Fukuoka, Fukuoka 810-0022, Japan
  • Kuramitsu Hospital /ID# 268751
    Fukuoka, Fukuoka 819-0037, Japan
  • Kokura Mental Clinic /ID# 268031
    Kitakyushu, Fukuoka 802-0006, Japan
  • Kawamura Mental Clinic /ID# 268325
    Sapporo, Hokkaido 001-0023, Japan
  • Yutaka Clinic /ID# 268026
    Sagamihara, Kanagawa 252-0303, Japan
  • INSPIRA Clinical Research /ID# 267041
    San Juan, Puerto Rico 00918-3014, Puerto Rico
  • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065
    San Juan, Puerto Rico 00918, Puerto Rico
  • BDH Research /ID# 267025
    San Juan, Puerto Rico 00927, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Nov 2025, 12 months.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Sep 20, 2024
StartActual
Oct 15, 2024
Primary completionActual
Nov 12, 2025
CompletionActual
Dec 10, 2025
Results delay requested
Oct 12, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (3 Puerto Rico, 2 Japan)
  • Kaku Mental Clinic /ID# 268020 · Fukuoka, Japan
  • Kuramitsu Hospital /ID# 268751 · Fukuoka, Japan
  • INSPIRA Clinical Research /ID# 267041 · San Juan, Puerto Rico
  • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065 · San Juan, Puerto Rico
  • BDH Research /ID# 267025 · San Juan, Puerto Rico
Show 5 removed
  • Kaku Mental Clinic /ID# 268020 · Fukuoka, Japan
  • Kuramitsu Hospital /ID# 268751 · Fukuoka, Japan
  • INSPIRA Clinical Research /ID# 267041 · San Juan, Puerto Rico
  • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065 · San Juan, Puerto Rico
  • BDH Research /ID# 267025 · San Juan, Puerto Rico
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    5 sites added, 5 sites removed
    Show 5 added (3 Puerto Rico, 2 Japan)
    • Kaku Mental Clinic /ID# 268020 · Fukuoka, Japan
    • Kuramitsu Hospital /ID# 268751 · Fukuoka, Japan
    • INSPIRA Clinical Research /ID# 267041 · San Juan, Puerto Rico
    • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065 · San Juan, Puerto Rico
    • BDH Research /ID# 267025 · San Juan, Puerto Rico
    Show 5 removed
    • Kaku Mental Clinic /ID# 268020 · Fukuoka, Japan
    • Kuramitsu Hospital /ID# 268751 · Fukuoka, Japan
    • INSPIRA Clinical Research /ID# 267041 · San Juan, Puerto Rico
    • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065 · San Juan, Puerto Rico
    • BDH Research /ID# 267025 · San Juan, Puerto Rico
    + 1 other change: registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06605599
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 20, 2024
Start date
Oct 15, 2024
Primary completion
Nov 12, 2025
Completion
Dec 10, 2025
Last update
Oct 14, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-932

Start the discussion